- GSK Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
6-K Filing
GSK (GSK) 6-KResult of Agm
Filed: 5 May 21, 2:46pm
Resolution | Total votes for(1)(2) | % | Total votes against(2) | % | Total votes cast | Votes withheld(3) | |
1 | Receive and adopt the 2020 Annual Report | 3,475,135,362 | 98.81 | 41,757,734 | 1.19 | 3,516,893,096 | 11,603,440 |
2 | Approve the Annual report on remuneration | 3,272,132,033 | 93.14 | 240,932,159 | 6.86 | 3,513,064,192 | 15,444,148 |
3 | Re-election of Sir Jonathan Symonds | 3,499,343,831 | 99.52 | 16,763,629 | 0.48 | 3,516,107,460 | 12,371,547 |
4 | Re-election of Dame Emma Walmsley | 3,507,017,955 | 99.68 | 11,159,384 | 0.32 | 3,518,177,339 | 10,359,075 |
5 | Re-election of Charles Bancroft | 3,506,975,009 | 99.74 | 9,026,131 | 0.26 | 3,516,001,140 | 12,472,435 |
6 | Re-election of Vindi Banga | 3,496,064,409 | 99.43 | 19,904,292 | 0.57 | 3,515,968,701 | 12,509,463 |
7 | Re-election of Dr Hal Barron | 3,507,018,967 | 99.69 | 10,733,599 | 0.31 | 3,517,752,566 | 10,738,305 |
8 | Re-election of Dr Vivienne Cox | 3,497,451,811 | 99.46 | 18,813,391 | 0.54 | 3,516,265,202 | 12,207,081 |
9 | Re-election of Lynn Elsenhans | 3,434,728,312 | 97.69 | 81,301,678 | 2.31 | 3,516,029,990 | 12,440,783 |
10 | Re-election of Dr Laurie Glimcher | 3,508,174,526 | 99.77 | 7,947,259 | 0.23 | 3,516,121,785 | 12,353,907 |
11 | Re-election of Dr Jesse Goodman | 3,506,872,640 | 99.74 | 9,131,605 | 0.26 | 3,516,004,245 | 12,467,159 |
12 | Re-election of Iain Mackay | 3,501,889,913 | 99.56 | 15,637,087 | 0.44 | 3,517,527,000 | 10,951,129 |
13 | Re-election of Urs Rohner | 3,484,061,208 | 99.10 | 31,702,634 | 0.90 | 3,515,763,842 | 12,752,529 |
14 | Re-appointment of the auditor | 3,512,936,007 | 99.84 | 5,521,996 | 0.16 | 3,518,458,003 | 10,024,350 |
15 | Remuneration of the auditor | 3,511,280,034 | 99.82 | 6,176,678 | 0.18 | 3,517,456,712 | 11,022,183 |
16 | Authority for the company to make donations to political organisations and incur political expenditure | 3,440,815,513 | 98.36 | 57,276,887 | 1.64 | 3,498,092,400 | 30,393,327 |
17 | Authority to allot shares | 3,362,807,250 | 95.66 | 152,632,653 | 4.34 | 3,515,439,903 | 13,038,799 |
18 | Disapplication of pre-emption rights - general power(4) | 3,368,593,428 | 95.88 | 144,660,127 | 4.12 | 3,513,253,555 | 15,222,364 |
19 | Disapplication of pre-emption rights - in connection with an acquisition or specified capital investment(4) | 3,291,504,396 | 93.68 | 221,978,886 | 6.32 | 3,513,483,282 | 14,999,454 |
20 | Authority for the company to purchase its own shares(4) | 3,449,168,275 | 98.36 | 57,436,714 | 1.64 | 3,506,604,989 | 21,875,135 |
21 | Exemption from statement of senior statutory auditor's name | 3,477,878,016 | 99.47 | 18,543,893 | 0.53 | 3,496,421,909 | 31,294,363 |
22 | Authority for reduced notice of a general meeting other than an AGM(4) | 3,286,542,818 | 93.50 | 228,494,172 | 6.50 | 3,515,036,990 | 12,675,849 |
(1) | The "for" votes include those giving the Chairman discretion. In line with the notification issued to American Depositary Receipt (ADR) holders last year, GSK did not instruct its ADR Depositary to vote any unvoted ADRs in respect of the AGM resolutions. |
(2) | Votes "for" and "against" are expressed as a percentage of the total votes cast. |
(3) | A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "for" or "against" a resolution. |
(4) | Indicates Special Resolutions requiring a 75% majority. |
GSK's Twenty first AGM (2021) | GSK's Twentieth AGM (2020) | |
Issued share capital (excluding Treasury Shares) | 5,031,444,276 | 5,017,091,542 |
Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares) | 70.11% | 72.60% |
Total shareholder population | 100,906 | 105,353 |
Total number of proxies lodged | 6,089 | 6,268 |
% of shareholders who lodged proxies | 6.03% | 5.95% |
GlaxoSmithKline plc | |
(Registrant) | |
Date: May 05, 2021 | |
By:/s/ VICTORIA WHYTE -------------------------- | |
Victoria Whyte | |
Authorised Signatory for and on | |
behalf of GlaxoSmithKline plc |